Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share

The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.

See why the elites are pouring billions into gold.

Bassil I. Dahiyat net worth and biography

Bassil Dahiyat Biography and Net Worth

CEO of Xencor

Dr. Dahiyat has been Xencor’s president and chief executive officer since the Company’s incorporation in August 1997, and is the co-founder of Xencor, and co-inventor of Xencor’s breakthrough XmAb® technology. He has led the Company in raising over $700 million in public and private financing, creating a diverse portfolio of monoclonal antibody clinical programs for the treatment of life-threatening and debilitating diseases, and establishing alliances with leading biopharmaceutical companies that generated over $400 million in upfront payments. He has co-authored numerous scientific papers in the fields of protein design and drug delivery, is an inventor of over 30 US and numerous foreign patents and has received scientific awards from the American Chemical Society, the Controlled Release Society, the Protein Society and Caltech. Dr. Dahiyat received a Ph.D. in chemistry from Caltech and B.S. and M.S.E. degrees in biomedical engineering from Johns Hopkins University.

What is Bassil I. Dahiyat's net worth?: The estimated net worth of Bassil I. Dahiyat is at least $7.13 million as of March 11th, 2024. Dr. Dahiyat owns 351,894 shares of Xencor stock worth more than $7,129,372 as of April 26th. This net worth evaluation does not reflect any other assets that Dr. Dahiyat may own. Additionally, Dr. Dahiyat receives an annual salary of $1,080,000.00 as CEO at Xencor. Learn More about Bassil I. Dahiyat's net worth.
How old is Bassil I. Dahiyat?: Dr. Dahiyat is currently 54 years old. There are 5 older executives and no younger executives at Xencor. Learn More on Bassil I. Dahiyat's age.
What is Bassil I. Dahiyat's salary?: As the CEO of Xencor, Inc., Dr. Dahiyat earns $1,080,000.00 per year. Learn More on Bassil I. Dahiyat's salary.
How do I contact Bassil I. Dahiyat?: The corporate mailing address for Dr. Dahiyat and other Xencor executives is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. Xencor can also be reached via phone at (626) 305-5900 and via email at [email protected]. Learn More on Bassil I. Dahiyat's contact information.
Has Bassil I. Dahiyat been buying or selling shares of Xencor?: Bassil I. Dahiyat has not been actively trading shares of Xencor over the course of the past ninety days. Learn More on Bassil I. Dahiyat's trading history.
Who are Xencor's active insiders?: Xencor's insider roster includes Bassil Dahiyat (CEO), and Allen Yang (CMO). Learn More on Xencor's active insiders.
Are insiders buying or selling shares of Xencor?: In the last twelve months, insiders at the biopharmaceutical company sold shares 12 times. They sold a total of 179,848 shares worth more than $3,971,553.36. The most recent insider tranaction occured on March, 11th when CFO John J Kuch sold 849 shares worth more than $19,951.50. Insiders at Xencor own 5.0% of the company. Learn More about insider trades at Xencor.
Information on this page was last updated on 3/11/2024.

Bassil I. Dahiyat Insider Trading History at Xencor

Bassil I. Dahiyat Buying and Selling Activity at Xencor

Xencor Company Overview

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

Today's Range

Now: $20.37

$19.14

$20.41

50 Day Range

MA: $22.10

$18.21

$26.52

2 Week Range

Now: $20.37

$16.49

$28.96

Volume

199,183 shs

Average Volume

683,581 shs

Market Capitalization

$1.25 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.76

Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share

From Colonial Metals | Ad

See why the elites are pouring billions into gold.

Bassil Dahiyat Biography and Net Worth

What is Bassil I. Dahiyat's net worth?

How old is Bassil I. Dahiyat?

What is Bassil I. Dahiyat's salary?

How do I contact Bassil I. Dahiyat?

Has Bassil I. Dahiyat been buying or selling shares of Xencor?

Who are Xencor's active insiders?

Are insiders buying or selling shares of Xencor?